“Missing The Target: When Practitioners Harm More Than Heal” is the title of a two-day conference in Washington this week (June 14-15) hosted by PharmedOut.org at Georgetown. This is their third annual conference – this one focusing on how patient harms may result from industry promotions.
The full agenda and abstracts are now available online.
Some of the speakers:
- Rita Redberg, M.D., M.Sc., Archives of Internal Medicine Editor-in-Chief; professor of medicine, University of California, San Francisco
- Carl Elliott, M.D. Ph.D., author, White Coat, Black Hat; professor, University of Minnesota’s Center for Bioethics
- Kay Dickersin, Ph.D., director, Center for Clinical Trials, Johns Hopkins Center for Global Health
- Julie Taitsman, M.D., J.D., chief medical officer, Office of the Inspector General, U.S. Department of Health and Human Services
- Sharon Treat, J.D., executive director, National Legislative Association on Prescription Drug Prices
- Thomas M. Burton, Pulitzer Prize winning-journalist, The Wall Street Journal
- Shannon Brownlee, M.S., author, Overtreated; acting director, New America Foundation Health Policy Program
- Susan Wood, PhD, George Washington University
- Sean Flynn, JD, American University
- Joel Lexchin, MD, York University
- Barbara Mintzes, Therapeutics Initiative
Some of the topics:
- Marketing of antipsychotic medications and other drugs
- Potential health risks of CT scans and other medical devices
- Legislative and regulatory updates and solutions
- The role of industry, media, and payers in informing and protecting patients
- The Underuse of Classic Drugs
- Are Medical Devices and Drugs Adequately Regulated?
- Protecting Patients in Industry-Funded Trials
- Pharmaceutical Marketing and Adverse Health Outcomes
Comments are closed.